: Dupilumab is a fully human monoclonal antibody that acts by inhibiting the interleukin (IL)-4 receptor subunit α, and hence the IL-4 and IL-13 signalling pathway. Dupilumab treatment has been linked to the onset of T helper (Th)-17 driven inflammatory diseases, including cases of seronegative arthritis and enthesitis. To date, dupilumab-associated inflammatory arthritis (DAIA) represents a relatively not well-known adverse event, initially reported in single cases or case series reports. Indeed, the onset of DAIA may be not promptly recognised, and is probably underestimated. Herein, we reviewed the available English literature regarding arthritis and enthesitis onset during dupilumab treatment for AD, aiming to improve a rapid recognition, and thus a prompt treatment of these diseases.
Dupilumab associated inflammatory arthritis: a literature review
Patruno, Cataldo
2023-01-01
Abstract
: Dupilumab is a fully human monoclonal antibody that acts by inhibiting the interleukin (IL)-4 receptor subunit α, and hence the IL-4 and IL-13 signalling pathway. Dupilumab treatment has been linked to the onset of T helper (Th)-17 driven inflammatory diseases, including cases of seronegative arthritis and enthesitis. To date, dupilumab-associated inflammatory arthritis (DAIA) represents a relatively not well-known adverse event, initially reported in single cases or case series reports. Indeed, the onset of DAIA may be not promptly recognised, and is probably underestimated. Herein, we reviewed the available English literature regarding arthritis and enthesitis onset during dupilumab treatment for AD, aiming to improve a rapid recognition, and thus a prompt treatment of these diseases.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
